SpyGlass Pharma, Inc. (SGP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SpyGlass Pharma, Inc. (SGP) has a cash flow conversion efficiency ratio of 0.094x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.33 Million) by net assets ($-98.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SpyGlass Pharma, Inc. - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how SpyGlass Pharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SpyGlass Pharma, Inc. total liabilities for a breakdown of total debt and financial obligations.
SpyGlass Pharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SpyGlass Pharma, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Odfjell SE
OL:ODF
|
0.051x |
|
Sido Muncul PT
JK:SIDO
|
0.126x |
|
Ceepower Co Ltd
SHE:300062
|
0.027x |
|
CEWE Stiftung & Co. KGaA
XETRA:CWC
|
-0.010x |
|
Independent Bank Corporation
NASDAQ:IBCP
|
0.036x |
|
Linkage Software Co Ltd
SHG:688588
|
0.037x |
|
Admie Holding S.A
AT:ADMIE
|
0.048x |
|
Zhejiang Unifull Industrial Fibre Co Ltd
SHE:002427
|
0.052x |
Annual Cash Flow Conversion Efficiency for SpyGlass Pharma, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of SpyGlass Pharma, Inc. from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see SGP market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-98.84 Million | $-32.70 Million | 0.331x | -9.16% |
| 2024-12-31 | $-60.47 Million | $-22.03 Million | 0.364x | -2.14% |
| 2023-12-31 | $-32.99 Million | $-12.28 Million | 0.372x | -- |
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intra… Read more